1
|
Zhu J, Wang J, Li Y. Recent advances in magnetic nanocarriers for tumor treatment. Biomed Pharmacother 2023; 159:114227. [PMID: 36638597 DOI: 10.1016/j.biopha.2023.114227] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 12/25/2022] [Accepted: 01/05/2023] [Indexed: 01/12/2023] Open
Abstract
Magnetic nanocarriers are nano-platforms that integrate multiple moieties based on magnetic nanoparticles for diagnostic and therapeutic purposes. In recent years, they have become an advanced platform for tumor treatment due to their wide application in magnetic resonance imaging (MRI), biocatalysis, magneto-thermal therapy (MHT), and photoresponsive therapy. Drugs loaded into magnetic nanocarriers can efficiently be directed to targeted areas by precisely reshaping their structural properties. Magnetic nanocarriers allow us to track the location of the therapeutic agent, continuously control the therapeutic process and eventually assess the efficacy of the treatment. They are typically used in synergistic therapeutic applications to achieve precise and effective tumor treatment. Here we review their latest applications in tumor treatment, including stimuli-responsive drug delivery, MHT, photoresponsive therapy, immunotherapy, gene therapy, and synergistic therapy. We consider reducing toxicity, improving antitumor efficacy, and the targeting accuracy of magnetic nanocarriers. The challenges of their clinical translation and prospects in cancer therapy are also discussed.
Collapse
Affiliation(s)
- Jianmeng Zhu
- Clinical Laboratory of Chun'an First People's Hospital, Zhejiang Provincial People's Hospital Chun'an Branch, Hangzhou Medical College Affiliated Chun'an Hospital, Hangzhou, Zhejiang, PR China.
| | - Jian Wang
- Clinical Laboratory of Chun'an First People's Hospital, Zhejiang Provincial People's Hospital Chun'an Branch, Hangzhou Medical College Affiliated Chun'an Hospital, Hangzhou, Zhejiang, PR China
| | - Yiping Li
- Clinical Laboratory of Chun'an First People's Hospital, Zhejiang Provincial People's Hospital Chun'an Branch, Hangzhou Medical College Affiliated Chun'an Hospital, Hangzhou, Zhejiang, PR China
| |
Collapse
|
2
|
Vinh Nguyen P, Hervé-Aubert K, Lajoie L, Misericordia Y, Chourpa I, David S, Allard-Vannier E. WITHDRAWN: In vitro synergistic activity of cisplatin and EGFR-targeted nanomedicine of anti-Bcl-xL siRNA in a non-small lung cancer cell line model. Int J Pharm 2023; 632:122335. [PMID: 36283640 DOI: 10.1016/j.ijpharm.2022.122335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 10/13/2022] [Accepted: 10/18/2022] [Indexed: 11/29/2022]
Abstract
This article was withdrawn from International Journal of Pharmaceutics in order to be published in International Journal of Pharmaceutics: X. The Publisher apologizes for any inconvenience this may cause.
Collapse
Affiliation(s)
- Phuoc Vinh Nguyen
- EA6295 Nanomédicaments et Nanosondes, Université de Tours, Tours, France; School of Medicine, Vietnam National University Ho Chi Minh City, Ho Chi Minh City, Vietnam
| | - Katel Hervé-Aubert
- EA6295 Nanomédicaments et Nanosondes, Université de Tours, Tours, France
| | - Laurie Lajoie
- ISP UMR1282, INRAE, équipe BioMAP, Université de Tours, Tours, France
| | - Yoann Misericordia
- EA6295 Nanomédicaments et Nanosondes, Université de Tours, Tours, France
| | - Igor Chourpa
- EA6295 Nanomédicaments et Nanosondes, Université de Tours, Tours, France
| | - Stéphanie David
- EA6295 Nanomédicaments et Nanosondes, Université de Tours, Tours, France
| | | |
Collapse
|
3
|
siRNA and targeted delivery systems in breast cancer therapy. CLINICAL & TRANSLATIONAL ONCOLOGY : OFFICIAL PUBLICATION OF THE FEDERATION OF SPANISH ONCOLOGY SOCIETIES AND OF THE NATIONAL CANCER INSTITUTE OF MEXICO 2022; 25:1167-1188. [PMID: 36562927 DOI: 10.1007/s12094-022-03043-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Accepted: 12/05/2022] [Indexed: 12/24/2022]
Abstract
Recently, nucleic acid drugs have been considered as promising candidates in treatment of various diseases, especially cancer. Because of developing resistance to conventional chemotherapy, use of genetic tools in cancer therapy appears inevitable. siRNA is a RNAi tool with capacity of suppressing target gene. Owing to overexpression of oncogenic factors in cancer, siRNA can be used for suppressing those pathways. This review emphasizes the function of siRNA in treatment of breast tumor. The anti-apoptotic-related genes including Bcl-2, Bcl-xL and survivin can be down-regulated by siRNA in triggering cell death in breast cancer. STAT3, STAT8, Notch1, E2F3 and NF-κB are among the factors with overexpression in breast cancer that their silencing by siRNA paves the way for impairing tumor proliferation and invasion. The oncogenic mechanisms in drug resistance development in breast tumor such as lncRNAs can be suppressed by siRNA. Furthermore, siRNA reducing P-gp activity can increase drug internalization in tumor cells. Because of siRNA degradation at bloodstream and low accumulation at tumor site, nanoplatforms have been employed for siRNA delivery to suppress breast tumor progression via improving siRNA efficacy in gene silencing. Development of biocompatible and efficient nanostructures for siRNA delivery can make milestone progress in alleviation of breast cancer patients.
Collapse
|
4
|
Nguyen PV, Hervé-Aubert K, Lajoie L, Misericordia Y, Chourpa I, David S, Allard-Vannier E. In vitro synergistic activity of cisplatin and EGFR-targeted nanomedicine of anti-Bcl-xL siRNA in a non-small lung cancer cell line model. Int J Pharm X 2022; 4:100139. [PMID: 36420371 PMCID: PMC9676141 DOI: 10.1016/j.ijpx.2022.100139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Apoptosis is an important process that directly affects the response of cancer cells to anticancer drugs. Among different factors involved in this process, the BcL-xL protein plays a critical role in inhibiting apoptosis induced by chemotherapy agents. Henceforth, its downregulation may have a synergistic activity that lowers the necessary dose of anticancer agents. In this study, anti-Bcl-xL siRNA were formulated within an EGFR-targeted nanomedicine with scFv ligands (NM-scFv) and its activity was tested in the non-small cell lung cancer (NSCLC) cell line H460. The obtained NMs-scFv anti-Bcl-xL were suitable for intravenous injection with sizes around 100 nm, a high monodispersity level and good siRNA complexation capacity. The nanocomplex's functionalization with anti-EGFR scFv ligands was shown to allow an active gene delivery into H460 cells and led to approximately 63% of gene silencing at both mRNA and protein levels. The NM-scFv anti-Bcl-xL improved the apoptotic activity of cisplatin and reduced the cisplatin IC50 value in H460 cells by a factor of around three from 0.68 ± 0.12 μM to 2.21 ± 0.18 μM (p < 0.01), respectively, in comparison to that of NM-scFv formulated with control siRNA (p > 0.05).
Collapse
Affiliation(s)
- Phuoc Vinh Nguyen
- EA6295 Nanomédicaments et Nanosondes, Université de Tours, Tours, France
- School of Medicine, Vietnam National University Ho Chi Minh city, Ho Chi Minh city, Viet Nam
| | - Katel Hervé-Aubert
- EA6295 Nanomédicaments et Nanosondes, Université de Tours, Tours, France
| | - Laurie Lajoie
- ISP UMR1282, INRAE, équipe BioMAP, Université de Tours, Tours, France
| | - Yoann Misericordia
- EA6295 Nanomédicaments et Nanosondes, Université de Tours, Tours, France
| | - Igor Chourpa
- EA6295 Nanomédicaments et Nanosondes, Université de Tours, Tours, France
| | - Stéphanie David
- EA6295 Nanomédicaments et Nanosondes, Université de Tours, Tours, France
| | | |
Collapse
|
5
|
Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells. Pharmaceutics 2022; 14:pharmaceutics14112537. [PMID: 36432729 PMCID: PMC9696063 DOI: 10.3390/pharmaceutics14112537] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2022] [Revised: 11/04/2022] [Accepted: 11/15/2022] [Indexed: 11/22/2022] Open
Abstract
According to Globocan 2020, breast cancer is considered one of the most common cancers affecting women and is one of the leading causes of death in over 100 countries. The available classical treatment options do not always give satisfactory outcomes, and some patients develop resistance to these treatments. This study aims to investigate the combination of nanovectorized siRNA directed against anti-apoptotic protein Survivin (siSurvivin) by targeted stealth magnetic siRNA nanovectors (TS-MSN), designed in our lab, with Doxorubicin (DOX), as an option for HER2+ breast cancer treatment. The hypothesis is that the pretreatment of the HER2+ breast cancer cell line SK-BR-3 with siSurvivin will induce apoptosis in the cancer cells and enhance the therapeutic efficacy of DOX, allowing a dose reduction of DOX and hence a reduction of potential side effects. TS-MSN are based on superparamagnetic iron oxide nanoparticles (SPIONs) covalently coupled with a fluorophore sulfocyanine-5 and polyethylene glycol 5000 (PEG5000) and functionalized with single-chain variable fragments (scFv) of an antibody targeting the HER2 membrane receptor. These covalently functionalized SPIONs are then complexed via electrostatic interactions with therapeutic siRNA and the cationic polymers, chitosan, and poly-L-arginine. TS-MSNsiSurvivin had an average size of 144 ± 30 nm, a PDI of 0.3, and a slightly positive zeta potential value of 10.56 ± 05.70 mV. The agarose gel electrophoresis assay confirmed that the siRNA is well-complexed into TS-MSN without leakage, as no free siRNA was detected. Moreover, siRNA in TS-MSN was protected from RNAse A degradation for up to 6 h at 37 °C. Formulations of TS-MSN with siSurvivin demonstrated in vitro gene knockdown up to 89% in the HER2+ breast cancer cell line SK-BR-3. Furthermore, qRT-PCR confirmed a significant Survivin mRNA relative expression inhibition (about 50%) compared to control siRNA or untreated cells. A combination protocol was evaluated between TS-MSN and Doxorubicin (DOX) for the first time. Therefore, SK-BR-3 cells were pretreated with TS-MSN formulated with siSurvivin at 50 nM for 24 h alone, before a DOX treatment at a concentration of 0.5 µM (corresponding to the IC50) was added for 48 h. The MTT cytotoxicity tests, performed after 72 h of treatment, revealed that the combination had a significant synergistic cytotoxic effect on SK-BR-3 cells compared to monotherapies or untreated cells. We confirmed that pretreatment of cells with siSurvivin potentializes the cytotoxic effect of DOX as an alternative approach for treating HER2+ breast cancer. In conclusion, a combination of anti-Survivin siRNA and DOX would be a good alternative in HER2+ breast cancer therapy.
Collapse
|
6
|
Halder J, Pradhan D, Biswasroy P, Rai VK, Kar B, Ghosh G, Rath G. Trends in iron oxide nanoparticles: a nano-platform for theranostic application in breast cancer. J Drug Target 2022; 30:1055-1075. [PMID: 35786242 DOI: 10.1080/1061186x.2022.2095389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Breast cancer (BC) is the deadliest malignant disorder globally, with a significant mortality rate. The development of tolerance throughout cancer treatment and non-specific targeting limits the drug's response. Currently, nano therapy provides an interdisciplinary area for imaging, diagnosis, and targeted drug delivery for BC. Several overexpressed biomarkers, proteins, and receptors are identified in BC, which can be potentially targeted by using nanomaterial for drug/gene/immune/photo-responsive therapy and bio-imaging. In recent applications, magnetic iron oxide nanoparticles (IONs) have shown tremendous attention to the researcher because they combine selective drug delivery and imaging functionalities. IONs can be efficaciously functionalised for potential application in BC therapy and diagnosis. In this review, we explored the current application of IONs in chemotherapeutics delivery, gene delivery, immunotherapy, photo-responsive therapy, and bio-imaging for BC based on their molecular mechanism. In addition, we also highlighted the effect of IONs' size, shape, dimension, and functionalization on BC targeting and imaging. To better comprehend the functionalization potential of IONs, this paper provides an outline of BC cellular development. IONs for BC theranostic are also reviewed based on their clinical significance and future aspects.
Collapse
Affiliation(s)
- Jitu Halder
- School of Pharmaceutical Science, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, India
| | - Deepak Pradhan
- School of Pharmaceutical Science, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, India
| | - Prativa Biswasroy
- School of Pharmaceutical Science, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, India
| | - Vineet Kumar Rai
- School of Pharmaceutical Science, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, India
| | - Biswakanth Kar
- School of Pharmaceutical Science, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, India
| | - Goutam Ghosh
- School of Pharmaceutical Science, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, India
| | - Goutam Rath
- School of Pharmaceutical Science, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, India
| |
Collapse
|
7
|
Synthesis and Characterization of a Fe 3O 4@PNIPAM-Chitosan Nanocomposite and Its Potential Application in Vincristine Delivery. Polymers (Basel) 2021; 13:polym13111704. [PMID: 34070978 PMCID: PMC8197087 DOI: 10.3390/polym13111704] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2021] [Revised: 05/14/2021] [Accepted: 05/20/2021] [Indexed: 12/26/2022] Open
Abstract
In this research, we conducted a systematic evaluation of the synthesis parameters of a multi-responsive core-shell nanocomposite (Fe3O4 nanoparticles coated by poly(N-isopropylacrylamide) (PNIPAM) in the presence of chitosan (CS) (Fe3O4@PNIPAM-CS). Scanning electron microscopy (SEM) was used to follow the size and morphology of the nanocomposite. The functionalization and the coating of Fe3O4 nanoparticles (Nps) were evaluated by the ζ-potential evolution and Fourier Transform infrared spectroscopy (FTIR). The nanocomposite exhibited a collapsed structure when the temperature was driven above the lower critical solution temperature (LCST), determined by dynamic light scattering (DLS). The LCST was successfully shifted from 33 to 39 °C, which opens the possibility of using it in physiological systems. A magnetometry test was performed to confirm the superparamagnetic behavior at room temperature. The obtained systems allow the possibility to control specific properties, such as particle size and morphology. Finally, we performed vincristine sulfate loading and release tests. Mathematical analysis reveals a two-stage structural-relaxation release model beyond the LCST. In contrast, a temperature of 25 °C promotes the diffusional release model. As a result, a more in-depth comprehension of the release kinetics was achieved. The synthesis and study of a magnetic core-shell nanoplatform offer a smart material as an alternative targeted release therapy due to its thermomagnetic properties.
Collapse
|
8
|
Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells. Eur J Pharm Biopharm 2020; 157:74-84. [DOI: 10.1016/j.ejpb.2020.10.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 09/04/2020] [Accepted: 10/08/2020] [Indexed: 01/01/2023]
|
9
|
Gauger AJ, Hershberger KK, Bronstein LM. Theranostics Based on Magnetic Nanoparticles and Polymers: Intelligent Design for Efficient Diagnostics and Therapy. Front Chem 2020; 8:561. [PMID: 32733850 PMCID: PMC7359411 DOI: 10.3389/fchem.2020.00561] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Accepted: 06/02/2020] [Indexed: 12/21/2022] Open
Abstract
Theranostics is a fast-growing field due to demands for new, efficient therapeutics which could be precisely delivered to the target site using multimodal imaging with enhancing auxiliary actions. In this review article we discuss theranostic nanoplatforms containing polymers and magnetic nanoparticles along with other components. Magnetic nanoparticles allow for both diagnostic and therapeutic (hyperthermia) capabilities, while polymers can be reservoirs for drugs and are easily functionalized for cell targeting. We focus on the most important design strategies to achieve optimal theranostic effects as well as the roles of different components included in theranostics, reviewing the literature from the last 5 years.
Collapse
Affiliation(s)
- Andrew J. Gauger
- Department of Chemistry, Indiana University, Bloomington, IN, United States
| | | | - Lyudmila M. Bronstein
- Department of Chemistry, Indiana University, Bloomington, IN, United States
- Department of Physics, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Moscow, Russia
| |
Collapse
|
10
|
Liu J, Liu W, Zhang K, Shi J, Zhang Z. A Magnetic Drug Delivery System with "OFF-ON" State via Specific Molecular Recognition and Conformational Changes for Precise Tumor Therapy. Adv Healthc Mater 2020; 9:e1901316. [PMID: 31858730 DOI: 10.1002/adhm.201901316] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 11/22/2019] [Indexed: 11/07/2022]
Abstract
To enhance the tumor-targeting and tumor cell-specific drug-release capacity of nano drug delivery systems, a magnetic resonance imaging-traceable, magnetic-targeted nanoplatform is developed, and the nanoplatform is prepared by capping mesoporous silica (MSN)-coated iron oxide nanoparticles (IONPs) with programmable DNA hairpin sensor "gates." In normal cells (HL-7702, human liver cells), the nanoplatform is able to entrap the loaded drugs, showing an "OFF" state; the nanoplatform is activated by endogenous miRNA-21 overexpressed in tumor cells (HepG2, human liver tumor cells), which serve as an exclusive key to unlock the nanoplatform through hybridization with programmable DNA hairpin, leading to a rapid drug release, showing an "ON" state. The nanoplatform exhibits high antitumor efficacy and low toxicity in in vitro and in vivo studies owing to its magnetic targeting and tumor cell-activated properties, paving the way for targeted and personalized tumor treatment and showing potential for clinical applications.
Collapse
Affiliation(s)
- Junjie Liu
- School of Pharmaceutical SciencesZhengzhou University Zhengzhou 450001 P. R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation Zhengzhou Henan Province 450001 P. R. China
- Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases Zhengzhou Henan Province 450001 P. R. China
| | - Wei Liu
- School of Pharmaceutical SciencesZhengzhou University Zhengzhou 450001 P. R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation Zhengzhou Henan Province 450001 P. R. China
- Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases Zhengzhou Henan Province 450001 P. R. China
| | - Kaixiang Zhang
- School of Pharmaceutical SciencesZhengzhou University Zhengzhou 450001 P. R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation Zhengzhou Henan Province 450001 P. R. China
- Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases Zhengzhou Henan Province 450001 P. R. China
| | - Jinjin Shi
- School of Pharmaceutical SciencesZhengzhou University Zhengzhou 450001 P. R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation Zhengzhou Henan Province 450001 P. R. China
- Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases Zhengzhou Henan Province 450001 P. R. China
| | - Zhenzhong Zhang
- School of Pharmaceutical SciencesZhengzhou University Zhengzhou 450001 P. R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation Zhengzhou Henan Province 450001 P. R. China
- Key laboratory of Targeting Therapy and Diagnosis for Critical Diseases Zhengzhou Henan Province 450001 P. R. China
| |
Collapse
|
11
|
Bruniaux J, Allard-Vannier E, Aubrey N, Lakhrif Z, Ben Djemaa S, Eljack S, Marchais H, Hervé-Aubert K, Chourpa I, David S. Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency. Int J Pharm 2019; 569:118572. [DOI: 10.1016/j.ijpharm.2019.118572] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2019] [Revised: 07/17/2019] [Accepted: 07/25/2019] [Indexed: 12/17/2022]
|
12
|
Villar-Alvarez E, Leal BH, Cambón A, Pardo A, Martínez-Gonzalez R, Fernández-Vega J, Al-Qadi S, Mosquera VX, Bouzas A, Barbosa S, Taboada P. Triggered RNAi Therapy Using Metal Inorganic Nanovectors. Mol Pharm 2019; 16:3374-3385. [PMID: 31188622 DOI: 10.1021/acs.molpharmaceut.9b00021] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The administration of small interfering RNA (siRNA) is a very interesting therapeutic option to treat genetic diseases such as Alzheimer's or some types of cancer, but its effective delivery still remains a challenge. Herein, Au nanorod (GNR)-based platforms functionalized with polyelectrolyte layers were developed and analyzed as potential siRNA nanocarriers. The polymeric layers were successfully assembled on the particle surfaces by means of the layer-by-layer assembly technique through the alternating deposition of oppositely charged poly(styrene)sulfonate, PSS, poly(lysine), PLL, and siRNA biopolymers, with a final hyaluronic acid layer in order to provide the nanoconstructs with a potential targeting ability as well as colloidal stability in physiological medium. Once the hybrid nanocarriers were obtained, the cargo release, their colloidal stability in physiological-relevant media, cytotoxicity, cellular internalization and uptake, and knockdown activity were studied. The present hybrid particles release the genetic material inside cells by means of a protease-assisted and/or a light-triggered release mechanism in order to control the delivery of the oligonucleotides on demand. In addition, the hybrid nanovectors were observed to be nontoxic to cells and could efficiently deliver the genetic material in the cell cytoplasms. The GNR-based nanocarriers proposed here can provide a suitable environment to load and protect a sufficient amount of the genetic material to allow an efficient and sustained knockdown gene expression for long (up to 93% for 72 h), thanks to the slow degradation of PLL, without the observation of adverse side toxic effects. It was also found that the silencing activity was enhanced with the number of siRNA layers assembled in the nanoplatforms.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Víctor X Mosquera
- Departamento de Cirugía Cardíaca, Complexo Hospitalario Universitario A Coruña , Instituto de Investigación Biomédica de A Coruña (INIBIC) , 15006 A Coruña , Spain
| | - Alberto Bouzas
- Departamento de Cirugía Cardíaca, Complexo Hospitalario Universitario A Coruña , Instituto de Investigación Biomédica de A Coruña (INIBIC) , 15006 A Coruña , Spain
| | | | | |
Collapse
|
13
|
Versatile electrostatically assembled polymeric siRNA nanovectors: Can they overcome the limits of siRNA tumor delivery? Int J Pharm 2019; 567:118432. [DOI: 10.1016/j.ijpharm.2019.06.023] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Revised: 06/04/2019] [Accepted: 06/10/2019] [Indexed: 11/20/2022]
|
14
|
Chen Y, Sun L, Guo D, Wu Z, Chen W. Co-delivery of hypoxia inducible factor-1α small interfering RNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells. J Gene Med 2017; 19. [PMID: 29106062 DOI: 10.1002/jgm.2998] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2017] [Revised: 10/21/2017] [Accepted: 10/22/2017] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Drug resistance cancer cells have become a major problem in chemotherapy. To solve this problem, the co-delivery of small interefering RNA (siRNA) and 5-fluorouracil chitosan nanoparticles was employed, aiming to reverse the multidrug resistance of gastric cancer SGC-7901 cells in vitro. METHODS Chitosan nanoparticles were prepared using an ionic gel method. siRNA nanoparticles were characterized by gel retardation assays. Particle size and zeta potential were measured to confirm nanoparticle formation. The transfection efficiency of siRNA was determined by flow cytometry and high-content screening. Western blotting and a quantitative real-time-polymerase chain reaction were used to assess the silencing efficiency of siRNA. Accumulation and efflux experiments for rhodamine-123, cell migration experiments, cell sensitivity analyses and cell apoptosis assays were used to determine whether siRNA could reverse multidrug resistance. A systemic toxicity assay was used to evaluate the safety of nanoparticles. RESULTS Compared to naked siRNA, the co-delivery system demonstrated a higher transfection efficiency and gene silencing efficiency by inhibiting the efflux of P-glycoprotein and cell migration. Moreover, the combination treatment with siRNA and 5-fluorouracil co-delivered by chitosan nanoparticles can increase the sensitivity of drug resistance cells and cell apoptosis. Finally, the safety of nanoparticles was evaluated in vivo and the results obtained suggested that nanoparticles did not have any obvious toxicity. CONCLUSIONS Co-delivery of siRNA and 5-fluorouracil chitosan nanoparticles is an attractive strategy for overcoming multidrug resistance.
Collapse
Affiliation(s)
- Yunna Chen
- The College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.,Anhui Academy of Chinese Medicine, Anhui Hefei, China.,Institute of Drug Metabolism, Anhui University of Chinese Medicine, Hefei, China
| | - Li Sun
- The College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Dongdong Guo
- The College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.,Anhui Academy of Chinese Medicine, Anhui Hefei, China.,Institute of Drug Metabolism, Anhui University of Chinese Medicine, Hefei, China
| | - Ziteng Wu
- The College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.,Anhui Academy of Chinese Medicine, Anhui Hefei, China.,Institute of Drug Metabolism, Anhui University of Chinese Medicine, Hefei, China
| | - Weidong Chen
- The College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.,Anhui Academy of Chinese Medicine, Anhui Hefei, China.,Institute of Drug Metabolism, Anhui University of Chinese Medicine, Hefei, China
| |
Collapse
|